Managing large cell lymphoma

Annals of Oncology

Volumn 17, Issue SUPPL. 4, 2006, Pages

  Gisselbrecht, Christian ^a   Mounier, N ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Autologous stem cell transplantation; Chemotherapy; Large cell lymphoma; Risk factors; Rituximab

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, LARGE-CELL; STEM CELL TRANSPLANTATION;

EID: 33646892806     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj991     Document Type: Conference Paper

References (17)

1. Harris N. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
2. Gisselbrecht C, Gaulard P, Lepage E et al. For the GELA. Prognostic significance of T-cell phenotype in aggressive non Hodgkin's lymphomas. Blood 1998; 92: 76-82.
3. Alizadeh AA, Elsen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
4. Mounier N, Brière J, Gisselbrecht C et al. For the Groupe d'Etude des Lymphomes de l'Adulte. Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphome (DLBCL) overcomes Bcl2 associated chemotherapy resistance. Blood 2003; 101: 4279-4284.
5. Reyes F, Lepage E, Ganem G et al. Groupe d'Etude des Lymphomes de l'Adulte (GELA) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-1205.
6. Coiffier B, Gisselbrecht C, Herbrecht R et al. LNH84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018-1026.
7. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVPB regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Blood 2003; 102: 4284-4289.
8. Pfreundschuh M, Trümper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
9. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high dose therapy in poor risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomse de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
10. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1296.
11. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-hodgkin's lymphoma cooperative group. J Clin Oncol 1998; 16: 2796-2802.
12. Milpied N, Deconinck E, Gailllard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. N Engl J Med 2004; 350: 1287-1295.
13. Mounier N, Gisselbrecht C, Brière J et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2004; 22: 2826-2834.
14. Coiffier B, Lepage E, Brière J et al. CHOP plus Rituximab with CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma. A Groupe d'Etude des Lymphomes de l'Adulte study. N Engl J Med 2002; 346: 235-242.
15. Feugier P, Van Hoff A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
16. Pfreundschuh M, Truemper L, Gill D et al. First analysis of the completed Mabthera international (MinT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of Rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favourable subgroup with IPI = 0 and no bulky disease. Blood 2004; 104: Abstr 157.
17. 18Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381.